Losartan improves measures of activity, inflammation, and oxidative stress in older mice

Experimental Gerontology

Volumn 58, Issue , 2014, Pages 174-178

  Lin, Chung Hao ^a,b   Yang, Huanle ^a   Xue, Qian Li ^a   Chuang, Yi Fang ^c   Roy, Cindy N ^a   Abadir, Peter ^a   Walston, Jeremy D ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Angiotensin II receptor blocker; Frailty; Inflammation; Oxidative stress; Renin angiotensin system; Sarcopenia

Indexed keywords

CATALASE; GLUTATHIONE PEROXIDASE; INTERLEUKIN 6; LOSARTAN; MANGANESE SUPEROXIDE DISMUTASE; MESSENGER RNA; THIOBARBITURIC ACID REACTIVE SUBSTANCE; PLACEBO; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; AUTACOID; BIOLOGICAL MARKER; INTERLEUKIN-6, MOUSE;

AGE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CATALASE GENE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GPX GENE; INFLAMMATION; MNSOD; MOUSE; MUSCLE CONTRACTION; MUSCLE STRENGTH; NONHUMAN; OXIDATIVE STRESS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SARCOPENIA; SKELETAL MUSCLE; TREADMILL EXERCISE; TREATMENT OUTCOME; AGING; GRIP STRENGTH; LOCOMOTION; MOTOR ACTIVITY; QUADRICEPS FEMORIS MUSCLE; STANDING; TRAVEL; ANIMAL; BLOOD; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY; TIME;

AGE FACTORS; AGING; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BIOMARKERS; CATALASE; DISEASE MODELS, ANIMAL; FEMALE; GLUTATHIONE PEROXIDASE; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-6; LOSARTAN; MICE, INBRED C57BL; MOTOR ACTIVITY; MUSCLE, SKELETAL; OXIDATIVE STRESS; RENIN-ANGIOTENSIN SYSTEM; SARCOPENIA; TIME FACTORS;

EID: 84907353142     PISSN: 05315565     EISSN: 18736815     Source Type: Journal    
DOI: 10.1016/j.exger.2014.07.017     Document Type: Article

References (18)

1. Abadir P.M., Foster D.B., Crow M., et al. Identification and characterization of a functional mitochondrial angiotensin system. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:14849-14854.
2. Burks T.N., Cohn R.D. One size may not fit all: anti-aging therapies and sarcopenia. Aging (Albany NY) 2011, 3:1142-1153.
3. Burks T.N., Andres-Mateos E., Marx R., et al. Losartan restores skeletal muscle remodeling and protects against disuse atrophy in sarcopenia. Sci. Transl. Med. 2011, 3:82ra37.
4. Carter C.S., Groban L. Role of the renin-angiotensin system in age-related sarcopenia and diastolic dysfunction. Aging Health 2008, 4:37-46.
5. Dai Q., Xu M., Yao M., et al. Angiotensin AT1 receptor antagonists exert anti-inflammatory effects in spontaneously hypertensive rats. Br. J. Pharmacol. 2007, 152:1042-1048.
6. Ghisletta P., Spini D. An introduction to generalized estimating equations and an application to assess selectivity effects in a longitudinal study on very old individuals. J. Educ. Behav. Stat. 2004, 29:421-437.
7. Habashi J.P., Judge D.P., Holm T.M., et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006, 312:117-121.
8. Jo E., Lee S.R., Park B.S., et al. Potential mechanisms underlying the role of chronic inflammation in age-related muscle wasting. Aging Clin. Exp. Res. 2012, 24(5):412-422. Epub 2012 Jun 18. 10.3275/8464.
9. Marzetti E., Leeuwenburgh C. Skeletal muscle apoptosis, sarcopenia and frailty at old age. Exp. Gerontol. 2006, 41:1234-1238.
10. Ogawa S., Mori T., Nako K., et al. Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy. Hypertension 2006, 47:699-705.
11. Reagan-Shaw S., Nihal M., Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008, 22:659-661.
12. Rolland Y., Dupuy C., Van Abellan K.G., et al. Treatment strategies for sarcopenia and frailty. Med. Clin. North Am. 2011, 95:427-438. (ix).
13. Sukhanov S., Semprun-Prieto L., Yoshida T., et al. Angiotensin II, oxidative stress and skeletal muscle wasting. Am. J. Med. Sci. 2011, 342:143-147.
14. Sullivan-Gunn M.J., Lewandowski P.A. Elevated hydrogen peroxide and decreased catalase and glutathione peroxidase protection are associated with aging sarcopenia. BMC Geriatr. 2013, 13:104.
15. Takagi H., Mizuno Y., Yamamoto H., et al. Effects of telmisartan therapy on interleukin-6 and tumor necrosis factor-alpha levels: a meta-analysis of randomized controlled trials. Hypertens. Res. 2013, 36:368-373.
16. Vescovo G., Dalla L.L., Serafini F., et al. Improved exercise tolerance after losartan and enalapril in heart failure: correlation with changes in skeletal muscle myosin heavy chain composition. Circulation 1998, 98:1742-1749.
17. Walston J., Fedarko N., Yang H., et al. The physical and biological characterization of a frail mouse model. J. Gerontol. 2008, 63:391-398.
18. Yasar S., Xia J., Yao W., et al. Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study. Neurology 2013, 81:896-903.